Wang Zhi, Yang Li, Sun Shan
Pediatric Gastrointestinal Surgery, Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, People's Republic of China.
Gastroenterology, Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, People's Republic of China.
Infect Drug Resist. 2023 Feb 28;16:1183-1191. doi: 10.2147/IDR.S394614. eCollection 2023.
The present study was performed to evaluate the effect of intestinal microbiota transplantation (IMT) on intestinal flora and inflammatory factor levels in patients with ulcerative colitis (UC).
In this study, 94 UC patients who attended the Department of Proctology or the Department of Gastroenterology departments of Sinopharm Dongfeng General Hospital between April 2021 and April 2022 were identified as research participants and were assigned to the control or Research Groups via the random number table method, with 47 cases in each group. Interventions included oral mesalamine for patients in the control group and oral mesalamine plus IMT for those in the research group. Outcome measures included clinical efficacy, intestinal microbiota score, enteroscopy score, Sutherland index, inflammatory factor level, intestinal mucosal barrier function level, and adverse reactions.
Mesalamine plus IMT was associated with significantly higher treatment efficiency (97.8%) versus mesalamine alone (80.85%) (P<0.05). Mesalamine plus IMT provided a better intestinal microbiota balance and milder disease symptoms versus mesalamine, as evidenced by the significantly lower intestinal microbiota scores, colonoscopy scores, and Sutherland index (P<0.05). In post-treatment, patients with IMT exhibited more mitigated inflammatory responses than those without, as shown by the higher levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-17 (IL-17), and interleukin-23 (IL-23) (P<0.05). Significantly lower D-lactate and serum diamine oxidase (DAO) levels were observed after IMT intervention than those with mesalamine alone (P<0.05). IMT features no significant increase in adverse effects than the control group (P>0.05).
IMT efficiently ameliorates the intestinal microbiota conditions of UC patients, mitigates inflammatory responses in the body, and facilitates the restoration of intestinal mucosal barrier function with no significant increase in adverse effects.
本研究旨在评估肠道微生物群移植（IMT）对溃疡性结肠炎（UC）患者肠道菌群及炎症因子水平的影响。
本研究将2021年4月至2022年4月在国药东风总医院肛肠科或消化内科就诊的94例UC患者确定为研究对象，通过随机数字表法分为对照组和研究组，每组47例。干预措施包括对照组患者口服美沙拉嗪，研究组患者口服美沙拉嗪加IMT。观察指标包括临床疗效、肠道微生物群评分、肠镜评分、萨瑟兰指数、炎症因子水平、肠道黏膜屏障功能水平及不良反应。
美沙拉嗪加IMT的治疗有效率（97.8%）显著高于单纯美沙拉嗪（80.85%）（P<0.05）。与美沙拉嗪相比，美沙拉嗪加IMT能使肠道微生物群更平衡，疾病症状更轻，肠道微生物群评分、结肠镜评分和萨瑟兰指数显著更低（P<0.05）。治疗后，接受IMT的患者炎症反应比未接受IMT的患者更轻，肿瘤坏死因子-α（TNF-α）、白细胞介素-1β（IL-1β）、白细胞介素-17（IL-17）和白细胞介素-23（IL-23）水平更高（P<0.05）。IMT干预后D-乳酸和血清二胺氧化酶（DAO）水平显著低于单纯美沙拉嗪组（P<0.05）。IMT的不良反应发生率与对照组相比无显著增加（P>0.05）。
IMT能有效改善UC患者的肠道微生物群状况，减轻机体炎症反应，促进肠道黏膜屏障功能恢复，且不良反应无显著增加。
